Evidence map›Paper›PMID 25977879›Full record

ArticleEJNMMI research2014

Evaluation of repeated [(18)F]EF5 PET/CT scans and tumor growth rate in experimental head and neck carcinomas.

Antti Silvoniemi, Jonna Silén, Sarita Forsback, Eliisa Löyttyniemi, Aleksi R Schrey, Olof Solin, Reidar Grénman, Heikki Minn, Tove J Grönroos

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in EJNMMI research, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
0.3field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 4 citations in OpenAlex.

  1. Repeatability of tumour hypoxia imaging using [European journal of nuclear medicine and molecular imaging · 2018
    Trial
  2. Review
  3. Molecular mechanisms of hypoxia in cancer.Clinical and translational imaging · 2017
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Antti SilvoniemiTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland ; Department of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, FI-20521, Finland.
Jonna SilénTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland.
Sarita ForsbackTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland.
Eliisa LöyttyniemiDepartment of Biostatistics, University of Turku, Lemminkäisenkatu 1, Turku, FI-20520, Finland.
Aleksi R SchreyDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, FI-20521, Finland.
Olof SolinTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland.
Reidar GrénmanDepartment of Otorhinolaryngology - Head and Neck Surgery, Turku University Hospital, Turku, FI-20521, Finland.
Heikki MinnTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland ; Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FI-20521, Finland.
Tove J GrönroosTurku PET Centre, Medicity Research Laboratory, University of Turku, Tykistökatu 6A, Turku, FI-20520, Finland ; Department of Oncology and Radiotherapy, Turku University Hospital, Turku, FI-20521, Finland.
University of Turku · FITurku University Hospital · FITurku PET Centre · FI

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTumor hypoxia is linked to invasion and metastasis but whether this associates with tumor growth rate is not well understood. We aimed to study the relationship between hypoxia evaluated with the positron emission tomography (PET) tracer [(18)F]EF5 and tumor growth. Our second goal was to assess the variability in the uptake of [(18)F]EF5 in tumor between two scans.

methodsFour human head and neck squamous cell carcinoma (UT-SCC) cell lines were xenografted in flank or neck of nude mice, and tumor size was closely monitored over the study period. The tumors were clearly visible when the first [(18)F]EF5 scan was acquired. After an exponential growth phase, the tumors were imaged again with [(18)F]EF5 and also with (18)F-fluorodeoxyglucose ([(18)F]FDG).

resultsThere was a clear correlation between the percentage of tumor growth rate per day and the [(18)F]EF5 uptake in the latter scan (r = 0.766, p = 0.01). The uptake of [(18)F]EF5 in the first scan and the uptake of [(18)F]FDG did not significantly correlate with the tumor growth rate. We also observed considerable variations in the uptake of [(18)F]EF5 between the two scans.

conclusionsThe uptake of [(18)F]EF5 in the late phase of exponential tumor growth is associated with the tumor growth rate in mice bearing HNC xenografts.

Indexed as

[18F]EF5[18F]FDGHNSCCHypoxiaPET/CTTumor growth rateXenograft

Identifiers

PMID25977879
PMCPMC4412195
OpenAlexW2100958733

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.